Middle East & Africa Sarcopenia Treatment Market
No. of Pages: 70 | Report Code: BMIRE00030473 | Category: Life Sciences
No. of Pages: 70 | Report Code: BMIRE00030473 | Category: Life Sciences
The Middle East & Africa sarcopenia treatment market was valued at US$ 66.59 million in 2022 and is expected to reach US$ 90.55 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030. Rising Awareness About Sarcopenia Bolster Middle East & Africa Sarcopenia Treatment Market
The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of certain disorders, such as pathogenicity, target patients, prevention, and treatments, along with underlining the value of prompt diagnosis and treatment. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.
Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years. Middle East & Africa Sarcopenia Treatment Market Overview
The Middle East & Africa sarcopenic treatment market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The UAE and Saudi Arabia are among the most significant contributors to the market due to the rising incidence of orthopedic disorders. Increasing awareness among the large population about the use and benefits of nutritional supplements also benefits the market progress.
An increased risk of sarcopenia in South Africa is associated with the aging population, and inadequate food security and nutrient intake brought on by poverty. The sarcopenia treatment market in this country is anticipated to be driven by a distinct population-specific approach taken by health authorities for the diagnosis, treatment, and prevention of sarcopenia.
Middle East & Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Strategic insights for the Middle East & Africa Sarcopenia Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Middle East & Africa Sarcopenia Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Middle East & Africa Sarcopenia Treatment Strategic Insights
Get more information on this report Middle East & Africa Sarcopenia Treatment Report Scope
Report Attribute
Details
Market size in 2022
US$ 66.59 Million
Market Size by 2030
US$ 90.55 Million
Global CAGR (2022 - 2030)
3.9%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Treatment Type
By Distribution Channel
Regions and Countries Covered
Middle East and Africa
Market leaders and key company profiles
Get more information on this report Middle East & Africa Sarcopenia Treatment Regional Insights
Get more information on this report
Middle East & Africa Segmentation
The Middle East & Africa sarcopenia treatment market is categorized into treatment type, distribution channel, and country.
Based on treatment type, the Middle East & Africa is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Middle East & Africa share in 2022.
In terms of distribution channel, the Middle East & Africa is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Middle East & Africa share in 2022.
By country, the Middle East & Africa is segmented into Saudia Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa share in 2022.
Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Middle East & Africa .
1. Abbott Laboratories
2. Bayer AG
3. Nestle Health Science SA
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Amway Corp
8. GSK Plc
The Middle East & Africa Sarcopenia Treatment Market is valued at US$ 66.59 Million in 2022, it is projected to reach US$ 90.55 Million by 2030.
As per our report Middle East & Africa Sarcopenia Treatment Market, the market size is valued at US$ 66.59 Million in 2022, projecting it to reach US$ 90.55 Million by 2030. This translates to a CAGR of approximately 3.9% during the forecast period.
The Middle East & Africa Sarcopenia Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Sarcopenia Treatment Market report:
The Middle East & Africa Sarcopenia Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Sarcopenia Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Sarcopenia Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Sarcopenia Treatment Market
